BCT BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.…
Industry Peers
BiotechnologyKey Statistics
About BriaCell Therapeutics (TSE: BCT)
›
BriaCell Therapeutics (TSE: BCT) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 31 employees.
The shares were at 4.655 CAD on 18 November 2026, down 59.2% over 52 weeks. Its 52-week range is 3.680 CAD to 18.00 CAD: the price is 74.1% below the high and 26.5% above the low.
Its market capitalisation is 40.65M CAD.
BriaCell Therapeutics reports return on equity of -212.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 20.54M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.